The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection

Research output: Contribution to journalArticle

Abstract

Background: Direct-acting antiviral drugs (DAA) regimen improve the SVR rate. However, adverse effects often lead to therapy interruption. This underlines the importance to find some predictive parameters of response in order to consider the possibility of a shorter time of antiviral treatment in the appearance of adverse effects without affecting the success of the therapy. Objectives: We aimed to examine the HCVAg kinetics in the early phase of treatment and its predictive value of SVR in patients undergoing TPV/Peg-IFN/RBV treatment. Study design: Twenty-three patients infected by HCV genotype 1 (1a n= 11; 1b n= 12) were included in this prospective study. Results: At baseline the median Log of HCVAg concentration in RVR and EVR patients were 3.15. fmol/L and 3.45. fmol/L, respectively with no significant differences. The baseline median HCV-RNA to HCVAg ratio was 233.77, this ratio was significantly lower when measured on day 1 (27.52) and on day 6 (24.84) (p

Original languageEnglish
Pages (from-to)68-73
Number of pages6
JournalJournal of Clinical Virology
Volume69
DOIs
Publication statusPublished - Aug 1 2015

Keywords

  • EVRearly virological response
  • HCVcore antigen
  • Hepatitis C virus
  • RVRrapid virological response
  • SVRsustained virological response
  • Telaprevir

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection'. Together they form a unique fingerprint.

  • Cite this